8-K: Biohaven Reports Positive Degrader Data and Fourth Quarter and Full Year 2024 Financial Results

Biohaven announces FDA acceptance of troriluzole NDA with Priority Review, positive degrader data, and provides a review of recent accomplishments and financial results for Q4 and full year 2024.

Summary

• Biohaven reported its Q4 and full year 2024 financial results and provided an update on its business developments.
• The FDA accepted the NDA for troriluzole for spinocerebellar ataxia (SCA) with Priority Review, setting a PDUFA date in Q3 2025.
• As of December 31, 2024, Biohaven had approximately $489 million in cash, cash equivalents, marketable securities, and restricted cash.
• BHV-1300, an IgG degrader, achieved up to an 84% reduction in total IgG in a Phase 1 study with subcutaneous weekly 1000 mg dosing.
• First-in-human dosing with BHV-1400, a TRAP degrader for IgA nephropathy, showed a median reduction of 60% in aberrant Gd-IgA1 within four hours of a single 125 mg dose.
• First-in-human dosing with BHV-1600, a TRAP degrader for peripartum cardiomyopathy, has been well-tolerated in the first two dosing cohorts.
• Topline data from Phase 3 OCD trials for troriluzole are expected in 1H 2025 and 2H 2025.
• Topline results for BHV-7000 in major depressive disorder are expected in 2H 2025, and in focal epilepsy in 1H 2026.
• Data from the laser-evoked potential study and migraine proof-of-concept study with BHV-2100 are expected in 1H 2025.
• An FDA meeting to discuss the SMA registrational path for taldefgrobep alfa is expected in 1H 2025, with a Phase 2 study in obesity also planned for 1H 2025.
• A Phase 2/3 study for BHV-8000 in Parkinson's disease is set to begin in 1H 2025.
• Interim Phase 1 data for BHV-1510, an ADC, is anticipated in 2H 2025, and a Phase 1 trial for BHV-1530 is planned for 1H 2025.
• R&D expenses for the year ended December 31, 2024, were $795.9 million, compared to $373.3 million for the year ended December 31, 2023.
• The company reported a net loss of $846.4 million, or $9.28 per share, for the year ended December 31, 2024, compared to a net loss of $408.2 million, or $5.73 per share, for the same period in 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments in the pipeline and clinical trials, the significant net loss and increased R&D expenses raise concerns. The overall sentiment is cautiously optimistic.

Positives

• FDA acceptance and Priority Review for troriluzole NDA in SCA indicates potential for approval and commercialization in 2025.
• Positive Phase 1 data for BHV-1300 showing significant IgG reduction suggests potential in treating autoimmune diseases.
• Rapid and selective lowering of Gd-IgA1 with BHV-1400 in IgA nephropathy program shows promise for targeted immune-modulating treatment.
• Advancement of multiple degrader programs targeting various disease-causing proteins.
• Initiation of Phase 2/3 study for BHV-8000 in Parkinson's disease represents progress in neuroinflammatory disorder treatment.
• Strong cash position of $489 million provides financial flexibility for ongoing and planned clinical trials.
• Expanded collaboration with GeneQuantum and Merus N.V. to co-develop novel dual-targeted ADCs.

Negatives

• The company reported a significant net loss of $846.4 million for the year ended December 31, 2024.
• Increased R&D expenses to $795.9 million for the year ended December 31, 2024, compared to $373.3 million for the year ended December 31, 2023.
• BHV-7000 did not statistically differentiate from the comparator arm on the primary efficacy endpoint in the acute treatment of manic episodes associated with bipolar disorder in a 3-week trial.

Risks

• The success of Biohaven's product candidates depends on positive outcomes from clinical trials and regulatory approvals.
• Delays in clinical trial timelines or unfavorable results could negatively impact the company's prospects.
• Commercialization of troriluzole is contingent on FDA approval, which is not guaranteed.
• The company's high R&D expenses and net losses could strain its financial resources.
• Competition from other companies developing treatments for the same indications poses a risk.
• The company's reliance on collaborations with other companies for ADC development could be affected by the success of those partnerships.

Future Outlook

Biohaven anticipates significant milestones in 2025 and 2026 across its various programs, including potential commercial launch of troriluzole in SCA, topline data from Phase 3 OCD trials, and advancement of its degrader and ADC platforms.

Management Comments

• Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, stated that the company has made considerable progress in advancing its innovative and diversified portfolio.
• Dr. Coric highlighted the advancement of the company's degrader technology, with BHV-1300 lowering serum IgG by up to 84% from baseline.
• Dr. Coric believes the company is poised to deliver important milestones in 2025 and beyond, starting with the FDA accepting the troriluzole NDA filing resubmission and granting Priority Review.

Industry Context

Biohaven's focus on novel immune-modulating extracellular degrader platforms and next-generation ADC technology aligns with the industry's growing interest in targeted therapies and precision medicine. The company's efforts to address unmet needs in areas such as autoimmune diseases, neurological disorders, and cancer position it to potentially capture significant market share.

Comparison to Industry Standards

• The reported 84% reduction in total IgG with BHV-1300 is a competitive result when compared to other FcRn inhibitors like argenx's Vyvgart and UCB's Rystiggo, which have demonstrated similar IgG reduction levels in clinical trials.
• Biohaven's ADC platform, with its focus on novel site-specific conjugation chemistry, aims to improve upon existing ADC technologies used by companies like Seagen and ImmunoGen, which have faced challenges related to payload toxicity and off-target effects.
• The development of selective TRAP degraders targeting specific disease-causing proteins differentiates Biohaven from companies pursuing broader immune modulation approaches, such as those targeting cytokines or immune cell populations.

Stakeholder Impact

• Positive clinical trial results and potential drug approvals could benefit patients suffering from SCA, OCD, IgA nephropathy, Parkinson's disease, and other conditions.
• Shareholders may be concerned about the company's significant net loss and increased R&D expenses.
• Employees may be affected by changes in the company's strategic direction and resource allocation.
• The company's collaborations with other companies could impact its relationships with suppliers and partners.

Next Steps

• Prepare for potential commercial launch of troriluzole in SCA in 2025, pending FDA approval.
• Report topline data from two Phase 3 OCD trials in 1H 2025 and 2H 2025, respectively.
• Initiate BHV-8000 Phase 2/3 study in Parkinson's disease in 1H 2025.
• Advance Alzheimer's, MS and ARIA programs in 2025.
• Continue advancing enrollment in proof-of-concept trial with BHV-2100 in acute migraine; data from the laser-evoked potential study expected in 1H 2025.
• Expect FDA meeting to discuss SMA registrational path in 1H 2025.
• Initiate taldefgrobep Phase 2 study in obesity in 1H 2025.
• Advance Merus collaboration ADCs (undisclosed targets) and TopoIx ADCs in 2025.

Key Dates